huahaipharm(SH:600521)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,058,913,113.43, representing a year-on-year increase of 16.15%[4] - The net profit attributable to shareholders of the listed company was RMB 172,934,924.85, up 25.59% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 188,552,713.22, reflecting a 44.34% increase year-on-year[4] - The basic earnings per share for the period was RMB 0.12, representing a 20.00% increase[4] - The weighted average return on equity was 2.26%, an increase of 0.18 percentage points[4] - The net profit for Q1 2023 was CNY 168,505,392.26, an increase of 20.5% compared to CNY 139,878,030.56 in Q1 2022[22] - The total comprehensive income for Q1 2023 was CNY 165,996,029.57, compared to CNY 139,775,078.82 in Q1 2022, an increase of 18.7%[22] - The total profit for Q1 2023 was CNY 177,182,403.86, an increase from CNY 129,224,930.94 in Q1 2022, representing a growth of approximately 37.06%[31] - The net profit for Q1 2023 reached CNY 148,538,126.97, compared to CNY 106,376,314.80 in Q1 2022, marking an increase of about 39.67%[31] Cash Flow - The net cash flow from operating activities was RMB 373,933,429.54, showing a significant increase of 269.74%[4] - The cash flow from operating activities netted CNY 373,933,429.54, significantly higher than CNY 101,134,514.53 in the previous year, marking a growth of 269.5%[24] - Cash flow from operating activities for Q1 2023 was CNY 1,152,043,927.65, significantly up from CNY 540,029,542.11 in Q1 2022, indicating a growth of approximately 113.33%[32] - The total cash inflow from operating activities in Q1 2023 was CNY 2,150,341,175.61, while cash outflow was CNY 998,297,247.96, resulting in a net cash flow of CNY 1,152,043,927.65[32] Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,694,368,161.57, a 2.99% increase from the end of the previous year[5] - The total assets as of March 31, 2023, were CNY 18,694,368,161.57, compared to CNY 18,151,737,482.18 at the end of 2022, reflecting an increase of 3.0%[18] - The total liabilities increased to CNY 10,764,516,339.35 as of March 31, 2023, from CNY 10,406,116,493.24 at the end of 2022, marking a rise of 3.4%[17] - The total liabilities increased to CNY 8,429,117,242.25 in Q1 2023 from CNY 7,944,976,145.97 in Q4 2022, marking an increase of about 6.1%[29] - The company's total assets as of March 31, 2023, amounted to CNY 17,881,973,790.67, an increase from CNY 17,236,575,254.67 at the end of 2022[29] Operating Costs and Expenses - The total operating costs for Q1 2023 were CNY 1,791,603,923.39, up 13.4% from CNY 1,578,705,956.71 in Q1 2022[19] - The total operating expenses for Q1 2023 were CNY 1,915,233,073.00, compared to CNY 1,825,919,831.07 in the previous year, reflecting an increase of 4.9%[24] Research and Development - Research and development expenses for Q1 2023 were CNY 202,193,404.97, slightly down from CNY 217,360,827.03 in Q1 2022[19] - Research and development expenses decreased to CNY 89,062,323.41 in Q1 2023 from CNY 103,942,743.89 in Q1 2022, a reduction of about 14.4%[30] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Other Financial Metrics - The gross profit margin for Q1 2023 was approximately 13.0%, compared to 10.9% in Q1 2022[19] - The gross profit for Q1 2023 was CNY 616,191,891.56, up from CNY 518,773,151.52 in Q1 2022, indicating a gross margin improvement[30] - The company reported a foreign exchange loss of CNY 2,258,971.89 in Q1 2023, compared to a loss of CNY 50,234.73 in Q1 2022[22] Borrowings - The company raised CNY 1,430,000,000.00 through borrowings in Q1 2023, compared to CNY 1,005,085,600.00 in Q1 2022, indicating a growth of 42.2%[24] - The company received CNY 1,010,000,000.00 in cash from borrowings in Q1 2023, a significant increase from CNY 275,000,000.00 in Q1 2022, representing a growth of about 267.27%[32] Cash and Cash Equivalents - The company's cash and cash equivalents increased to CNY 1,728,714,585.72 as of March 31, 2023, from CNY 1,365,152,641.03 at the end of 2022, representing a growth of 26.7%[14] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 1,695,549,488.10, slightly down from CNY 1,720,947,195.78 at the end of Q1 2022[25] - The ending balance of cash and cash equivalents as of Q1 2023 was CNY 953,478,680.20, compared to CNY 587,657,165.25 at the end of Q1 2022, indicating an increase of approximately 62.14%[32]